. 2021 Aug 21;10(8):1014. doi: 10.3390/antibiotics10081014

Table 1.

Overview of included studies’ main features.

Author, yr [Reference]	Country	Design	No. of Centers	Study Period	Sample Size	MRSA Associated Endocarditis	Group		Primary Endpoints ¹	Mortality	Clinical Failure (Composite Outcome)	Relapse	Persistent BSI	Safety Assessment ²
Author, yr [Reference]	Country	Design	No. of Centers	Study Period	Sample Size	MRSA Associated Endocarditis	Daptomycin (Daily Dose, Treatment Duration, Combination Therapy [%, Drug])	Vancomycin (Trough Concentration or Daily Dose, Treatment Duration, Combination Therapy [%, Drug])	Primary Endpoints ¹	Mortality	Clinical Failure (Composite Outcome)	Relapse	Persistent BSI	Safety Assessment ²
Arshad S et al. 2017 [27]	USA	Retrospective matched cohort study	1	Nov 2009–Dec 2013	102 (46 DAP vs. 56 VAN)	DAP: 19/46 VAN: 13/56	N/A 4–8 weeks N/A	N/A 4–8 weeks N/A	1–3, 5	DAP: 11/46 VAN: 6/56	DAP: 15/46 10/56	DAP: 1/46 1/56	N/A	N/A
Claeys C et al. 2016 [33]	USA	Retrospective matched cohort study	3	Jan 2010–Mar 2015	262 (131 VAN vs. 131 DAP)	DAP: 25/131 VAN: 25/131	8.2 mg/kg (IQR, 6.4–10.0) N/A 24.4% (13% ceftaroline, 6.9% rifampin)	17.7 mg/L (IQR, 13–222.0) N/A 20.6% (10.7% ceftaroline, 4.6% rifampin)	1–6	DAP: 8/131 VAN: 20/131	DAP: 38/131 VAN: 59/131	DAP: 0/131 VAN: 0/131	DAP: 20/131 VAN: 37/131	DAP: 2 (3/131) VAN: 1 (12/131)
Moise PA et al. 2016 [32]	USA	Retrospective matched cohort study	11	2005–2012	170 (85 DAP vs. 85 VAN)	31/170 (no group subdivision)	6 mg/kg (IQR 6–8) 16 days (IQR, 10–35) 74% (13% gentamicin, 15% rifampin, 46% β-lactam)	17.5 mg/L (IQR,14.0–22.0) 16 days (IQR, 9–31) 98% (16% gentamicin, 11% rifampin, 71% β-lactam)	1–4, 6	DAP: 15/85 VAN: 18/85	DAP: 9/85 VAN: 20/85	DAP: 0/85 VAN: 0/85	DAP: 8/72 VAN: 6/66	DAP: 1 (6/64) VAN: 1 (14/62)
Moore CL et al. 2012 [29]	USA	Retrospective case–control study	1	2005–2009	177 (59 DAP vs. 118 VAN)	DAP: 17/59 VAN: 34/118	6 mg/kg (dose adjustment if GFR ≤30 mL/min) 12 days (IQR, 8–18) $38 % (aminoglycoside or rifampin for \geq$ 3 days)	10-20 mg/L 15 days (IQR, 10–24) $51 % (aminoglycoside or rifampin for \geq$ 3 days)	1–4, 6	DAP: 5/59 VAN: 24/118	DAP: 10/59 VAN: 37/118	DAP: 2/59 VAN: 6/118	N/A	DAP: 1 (1/59) VAN: 1 (13/63)
Weston A et al. 2014 [31]	USA	Retrospective case–control study	1	Jan 2001–Aug 2011	267 (50 DAP vs. 100 VAN)	DAP: 13/50 VAN: 11/100	6.8 mg/kg (range, 5.1–10.8) (dose adjustment if GFR ≤30 mL/min) Average 28 days N/A	15.3 μg/mL (range, 8.2–25.6) Average 21 days N/A	1–4	DAP: 8/50 VAN: 35/100	DAP: 17/50 VAN: 51/100	DAP: 6/50 VAN: 5/100	DAP: 7/50 VAN: 21/100	DAP: 2 (2/50) VAN: N/A
Murray KP et al. 2013 [30]	USA	Retrospective matched cohort study	4	Jan 2005–Mar 2012	170 (85 DAP vs. 85 VAN)	DAP: 20/85 VAN: 20/85	8.4 mg/kg (IQR, 6.3–9.9) 10 days (IQR, 8–17) 30.6% (14.1% aminoglycoside, 16.5% rifampin)	17.6 µg/mL (IQR, 14.9–21.2) 9 days (IQR, 6-16) 47.1% (25.9% aminoglycoside, 21.2% rifampin)	1–4	DAP: 3/85 VAN: 11/85	DAP: 17/85 VAN: 41/85	DAP: 0/85 VAN: 3/85	DAP: 16/85 VAN: 36/85	DAP: 2 (1/85) VAN: 1 (22/85)
Usery JB et al. 2015 [28]	USA	Retrospective cohort study	1	Jun 2008–Nov 2010	122 (53 DAP vs. 54 VAN)	DAP: 6/53 VAN: 6/54	6.7 mg/kg (range, 4.9–8.5) 16.4 days (range, 6.8–26) N/A	13.6 mg/kg (range, 9.6–17.6) 13.6 days (range, 6.5–20.7) N/A	1–3, 7	DAP: 10/53 VAN: 5/54	DAP: 11/53 VAN: 9/54	DAP: 4/42 VAN: 8/49	DAP: 19/53 VAN: 11/54	N/A
Rehm SJ et al. 2008 [26]	International	Subset analysis of an open-label randomized trial	Multicentre	Aug 2002–Mar 2005	88 (45 DAP vs. 43 VAN plus gentamicin)	DAP: 13/45 VAN: 10/43	6 mg/kg 10-14 days for uncomplicated bacteraemia; at least 28 days for complicated bacteraemia and endocarditis N/A	14.9 μg/mL 10-14 days for uncomplicated bacteraemia; at least 28 days for complicated bacteraemia and endocarditis 100% (gentamicin 1 mg/kg every 8 hours for the first 4 days of treatment)	1–4, 6, 7	DAP: 12/45 VAN: 8/43	DAP: 25/45 VAN: 29/43	DAP: 12/45 VAN: 9/43	DAP: 3/45 VAN: 7/43	DAP: 1, 3 (3/45) VAN: 1, 3 (7/43)

¹ Endpoints include the following: (1) mortality (including all-cause mortality, in-hospital mortality, 30-day mortality, 60-day mortality); (2) clinical failure (composite endpoint); (3) relapse (including 30/42-day relapse, 60-day MRSA BSI-related re-admission); (4) persistent BSI (including bacteraemia persistent $\geq$ 5/7 days, microbiologic failure); (5) duration of hospitalization and therapy; (6) safety; (7) success (including clinical cure, negative blood cultures after 42 days since end of therapy). ² Safety assessment includes the following adverse events: (1) nephrotoxicity; (2) CK elevation; (3) all AEs.